Physician profile
Le Wang
NPI 1528277852
$3,137.68
in general payments reported to CMS, 2019-2025
33 companies · $22.14 in 2025
The $22.14 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $397 · 2021: $339 · 2022: $707 · 2023: $584 · 2024: $468 · 2025: $22.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $571 · Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $571.24 |
| Food and Beverage | $503.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $440.99 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $301.21 | 2019-2023 | Opdivo |
| Lilly USA, LLC | $287.27 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $253.03 | 2022-2024 | Cabometyx |
| Amgen INC. | $229.92 | 2019-2023 | |
| Janssen Biotech, INC. | $214.29 | 2021-2023 | Darzalex, Tecvayli |
| Pfizer INC. | $210.73 | 2019-2024 | |
| Incyte Corporation | $194.00 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $116.82 | 2019 | |
| Gilead Sciences, INC. | $111.91 | 2021-2023 | Trodelvy |
| Allergan, INC. | $99.35 | 2020 | |
| Beigene USA, INC. | $79.95 | 2022-2023 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $76.49 | 2023 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $76.48 | 2020-2021 | |
| Genentech USA, INC. | $66.18 | 2019-2024 | Polivy, Columvi, Lunsumio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.69 | 2022-2023 | Imfinzi |
| Merck Sharp & Dohme LLC | $37.07 | 2023-2024 | Keytruda, Lynparza |
| Novocure INC. | $31.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.59 | 2019 | |
| Clovis Oncology, INC. | $26.03 | 2021 | |
| Genzyme Corporation | $24.15 | 2022 | |
| Adc Therapeutics America, INC. | $22.14 | 2025 | |
| Abbvie INC. | $18.28 | 2019 | |
| Tactile Systems Technology INC | $17.50 | 2023 | Flexitouch Plus, Entre Plus |
| Tempus Ai, INC | $15.98 | 2024 | |
| Array Biopharma INC | $15.83 | 2023 | Braftovi, Lorbrena |
| Sobi, INC | $15.78 | 2022 | |
| Eisai INC. | $14.79 | 2023 | |
| Aadi Bioscience, INC. | $13.94 | 2023 | Fyarro |
| Novartis Pharmaceuticals Corporation | $13.67 | 2023 | |
| Blueprint Medicines Corporation | $13.34 | 2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $13.33 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Le Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.